IBEC signs an agreement for 1.5 million euros with Scranton Enterprises
The Institute for Bioengineering of Catalonia (IBEC) has signed an agreement for an initial investment round of one and a half million euros with Scranton Entreprises B.V. -an investment association headquartered in the Netherlands-, with the aim of developing technology that predicts the probability of implantation of embryos obtained through in vitro fertilization.
This agreement is the first to be established within the framework of the institute’s new initiative, the Open Innovation Lab, that offers companies and investors a platform to bring the cutting-edge research to patients and to the market faster. 



IBEC group leader Silvia Muro has been granted funding in MINECO’s ‘Explora Ciencia’ and ‘Explora Tecnología’ 2017 call.
The biotechnology company Iproteos, IBEC and the Vall d’Hebron Research Institute (VHIR) are set to develop an innovative treatment to slow down, stop and even reverse the growth of solid tumors, which represent more than 90% of cancer cases.
This year an IBEC project has won the Fira Recerca en Directe 2019’s public poll for most popular project, with 26.94% of the votes.